APTO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States...

Stats
Šios dienos apimtis	31 988.00
Vidutinė apimtis	78 452.00
Rinkos kapitalizacija	18.70M
EPS	$0 ( 2024-03-26 )
Kita pelno data	( $-0.820 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.00600 (0.50%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-05	Payne Fletcher	Buy	55 000	Employee Stock Option (Right to Buy)
2024-02-05	Bejar Rafael	Buy	35 000	Employee Stock Option (Right to Buy)
2024-02-05	Ledru Philippe	Buy	11 000	Employee Stock Option (Right to Buy)
2024-02-05	Rice William G.	Buy	70 000	Employee Stock Option (Right to Buy)
2024-02-05	Seizinger Bernd R.	Buy	3 333	Director Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 9 955 760 \| Sell: 550 471

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: 0.44 (neutral)

Signal:(54.823) Neutral

Aptose Biosciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
HCTI	0.957
RMRM	0.954
ATRS	0.95
LIQT	0.941
LABP	0.937
APLT	0.936
XLRN	0.925
BLU	0.914
TRKA	0.912
MNST	0.907

10 Labiausiai neigiamai susiję koreliacijos
NTGR	-0.922
EVBG	-0.921
SLAB	-0.912
TCON	-0.909
CPSI	-0.909
PI	-0.907
ENPH	-0.9
AUB	-0.898
TENB	-0.898
HONE	-0.894

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aptose Biosciences Inc Koreliacija - Valiuta/Žaliavos

0.60
( weak )

0.47
( neutral )

0.00
( neutral )

-0.46
( neutral )

-0.37
( neutral )

Aptose Biosciences Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-474 545 (0.00 %)
EPS:	$-7.72

FY	2023
Pajamos:	$0
Bruto pelnas:	$-474 545 (0.00 %)
EPS:	$-7.72

FY	2022
Pajamos:	$0
Bruto pelnas:	$-507 079 (0.00 %)
EPS:	$-6.67

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.